 Hydroxamic Acids
"Hydroxamic Acids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of weak acids with the general formula R-CONHOH.
| Descriptor ID |
D006877
|
| MeSH Number(s) |
D02.092.570.394 D02.241.511.372
|
| Concept/Terms |
Hydroxamic Acids- Hydroxamic Acids
- Acids, Hydroxamic
- Hydroxamic Acid
- Acid, Hydroxamic
|
Below are MeSH descriptors whose meaning is more general than "Hydroxamic Acids".
Below are MeSH descriptors whose meaning is more specific than "Hydroxamic Acids".
This graph shows the total number of publications written about "Hydroxamic Acids" by people in UAMS Profiles by year, and whether "Hydroxamic Acids" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 1 | 1 | | 2016 | 1 | 2 | 3 | | 2015 | 1 | 1 | 2 | | 2014 | 1 | 0 | 1 | | 2013 | 2 | 2 | 4 | | 2011 | 0 | 1 | 1 | | 2010 | 2 | 0 | 2 | | 2009 | 2 | 2 | 4 | | 2008 | 0 | 1 | 1 | | 2007 | 1 | 3 | 4 | | 2004 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Hydroxamic Acids" by people in Profiles over the past ten years.
-
Bisagno V, Bernardi MA, Sanz Blasco S, Urbano FJ, Garcia-Rill E. Differential effects of HDAC inhibitors on PPN oscillatory activity in vivo. Neuropharmacology. 2020 03 15; 165:107922.
-
Urbano FJ, Bisagno V, Mahaffey S, Lee SH, Garcia-Rill E. Class II histone deacetylases require P/Q-type Ca2+ channels and CaMKII to maintain gamma oscillations in the pedunculopontine nucleus. Sci Rep. 2018 09 03; 8(1):13156.
-
Chen G, Xu Z, Chang G, Hou J, Hu L, Zhang Y, Yu D, Li B, Chang S, Xie Y, Zhang Y, Wei R, Wu H, Xiao W, Sun X, Tao Y, Gao L, Dai B, Shi J, Zhu W. The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells. Oncol Rep. 2017 Jul; 38(1):488-496.
-
Jones JR, Cairns DA, Gregory WM, Collett C, Pawlyn C, Sigsworth R, Striha A, Henderson R, Kaiser MF, Jenner M, Cook G, Russell NH, Williams C, Pratt G, Kishore B, Lindsay J, Drayson MT, Davies FE, Boyd KD, Owen RG, Jackson GH, Morgan GJ. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J. 2016 12 09; 6(12):e506.
-
Raju I, Kaushal GP, Haun RS. Epigenetic regulation of KLK7 gene expression in pancreatic and cervical cancer cells. Biol Chem. 2016 11 01; 397(11):1135-1146.
-
Puvvada SD, Li H, Rimsza LM, Bernstein SH, Fisher RI, LeBlanc M, Schmelz M, Glinsmann-Gibson B, Miller TP, Maddox AM, Friedberg JW, Smith SM, Persky DO. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leuk Lymphoma. 2016 10; 57(10):2359-69.
-
Smith EM, Zhang L, Walker BA, Davenport EL, Aronson LI, Krige D, Hooftman L, Drummond AH, Morgan GJ, Davies FE. The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NF?B signalling pathway. Oncotarget. 2015 Jul 10; 6(19):17314-27.
-
Herzog C, Marisiddaiah R, Haun RS, Kaushal GP. Basement membrane protein nidogen-1 is a target of meprin ? in cisplatin nephrotoxicity. Toxicol Lett. 2015 Jul 16; 236(2):110-6.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|